Moore Capital Management, LP Insmed Inc Transaction History

Moore Capital Management, LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$22.0 - $69.71 $110,000 - $348,549	5,000 New	5,000 $335,000
Q3 2023 Nov 14, 2023	BUY	$19.86 - $26.93 $993,000 - $1.35 Million	50,000 New	50,000 $1.26 Million
Q3 2022 Nov 14, 2022	BUY	$20.88 - $28.21 $2.51 Million - $3.38 Million	119,972 New	119,972 $2.58 Million
Q1 2020 May 15, 2020	SELL	$13.63 - $33.98 $1.02 Million - $2.55 Million	-75,000 Closed	0 $0
Q4 2019 Feb 14, 2020	SELL	$16.12 - $24.98 $403,000 - $624,500	-25,000 Reduced 25.0%	75,000 $1.79 Million
Q2 2019 Aug 14, 2019	BUY	$23.0 - $32.19 $2.3 Million - $3.22 Million	100,000 New	100,000 $2.56 Million
Q4 2017 Feb 14, 2018	SELL	$26.43 - $31.78 $1.32 Million - $1.59 Million	-50,000 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$11.61 - $31.21 $580,500 - $1.56 Million	50,000	50,000 $1.56 Million

467

182M

2.27M

3.33M

Ticker INSM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 135,476,992
Market Cap $10B
Description
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversibl...

Get notified when there are updates to the investment portfolio of Moore Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Moore Capital Management, LP with notifications on news.